Tech Transfer eNews Blog
University-Industry Engagement Advisor

Stanford start-up developing lymphoma treatment files for IPO, seeks $115M

By Jesse Schwartz
Published: June 13th, 2018

A Stanford University biotech startup has filed for an IPO to advance its novel treatment for lymphoma.

The start-up, dubbed Forty Seven, is seeking $115 million from the IPO to advance its lead candidate 5F9, an antibody that targets the CD47 receptor in cancer cells to treat diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

In clinical studies for 5F9, the response rate for patients with DLBCL was 40%, with a complete response rate of 33%. In FL, those rates were 71% and 43% respectively.

“These preliminary data suggest that 5F9 may offer patients with DLBCL and FL a new treatment option that is both safe and easy to administer and that can rapidly induce benefit,” says Stanford professor Sonali Smith, who co-developed the antibody. “I am excited to continue evaluating 5F9 in the Phase 2 portion of this trial, as we learn more about the clinical utility of this potentially transformative agent.”

5F9 has already received a Fast Track designation from the FDA in relapsed or refractory DLBCL and FL. In seeking to expand the applications of the antibody, Forty Seven has partnered with Merck KGaA to pair 5F9 with the existing immunotherapy treatment Bavencio.

Source: Pharmafile

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment